Table 3: Representative inhibitors designed in the second round (N1 and N3 not shown here)

	R ₅ N N N N N O D				
	EI EI	$\begin{array}{ccc} & N & \\ R_6 & H & O \end{array}$	R ₈	O R ₉	
Compound No. ^a	R_5	R_6	R_7	R_8	R ₉
N2	tert-Butoxyl	Me	ⁱ Pr	ⁱ Bu	Et
N4	tert-Butoxyl	Me	ⁱ Pr	ⁱ Bu	Bn
N5	مرس م	ⁱ Pr	ⁱ Pr	Ph	Et
N9	0	ⁱ Pr	ⁱ Pr	ⁱ Bu	Et
N14	0	Bn	ⁱ Pr	ⁱ Bu	Et
N15	٥	ⁱ Bu	ⁱ Pr	ⁱ Bu	Et
N10	0	ⁱ Pr	ⁱ Pr	ⁱ Bu	OMe

^a In preliminary inhibition assays for SARS-CoV M^{pro}, the compounds in this table (expect N9) were less effective than N1, N3 and N9 and their accurate inhibition kinetic parameters were not determined.